Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

KPIs

Operating metrics that drive Amgen's business · fiscal year ends Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Metric	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30

Total Revenues — Worldwide ($M)($M)1	10,054	8,618	9,866	9,557	9,179	8,149	9,086	8,503	8,388	7,447	8,196	6,903
Other Revenues (Royalties, Milestone & Collaboration Revenues) — Worldwide ($M)($M)	517	400	499	420	408	276	370	352	347	329	363	355
Total Product Sales — Worldwide ($M)($M)5	9,537	8,218	9,367	9,137	8,771	7,873	8,716	8,151	8,041	7,118	7,833	6,548
Total Product Sales — United States ($M)($M)1	6,990	5,773	6,919	6,751	6,324	5,662	6,509	5,979	5,840	4,973	5,870	4,691
Total Product Sales — U.S. volume growth YoY (%)(%)	9.0%	8.0%		13.0%	13.0%	16.0%		34.0%	30.0%	29.0%
Total Product Sales — Rest of World (ROW) ($M)($M)1	2,547	2,445	2,448	2,386	2,447	2,211	2,207	2,172	2,201	2,145	1,963	1,857
Total Product Sales — Rest of World (ROW) volume growth YoY (%)(%)	8.0%	13.0%		16.0%	15.0%	11.0%		18.0%	15.0%	17.0%
Total Product Sales — Worldwide reported growth YoY (%)(%)	9.0%	4.0%	7.0%	12.0%	9.0%	11.0%	11.0%	24.0%	20.0%	22.0%	20.0%	5.0%
Total Product Sales — Worldwide volume growth YoY (%)(%)		9.0%				14.0%	15.0%	12.0%	10.0%	25.0%	23.0%
Total Product Sales — Worldwide net selling price change YoY (%)(%)		-2.0%				-6.0%					-3.0%
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide product sales ($M)($M)4	953	876	870	794	696	656	606	567	532	517	417	406
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — U.S. product sales ($M)($M)	510	465	517	442	361	343	315	281	270	273	201	183
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Rest of World (ROW) product sales ($M)($M)	443	411	353	352	335	313	291	286	262	244	216	223
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide reported sales growth YoY (%)(%)	37.0%	34.0%	44.0%	40.0%	31.0%	27.0%	45.0%	40.0%	25.0%	33.0%	25.0%	31.0%
Repatha (evolocumab — PCSK9 Inhibitor, Cardiovascular) — Worldwide volume growth YoY (%)(%)		35.0%	31.0%		36.0%	41.0%		41.0%	46.0%	44.0%	35.0%	43.0%
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide product sales ($M)($M)3	714	562	599	541	518	442	431	399	391	342	318	307
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — U.S. product sales ($M)($M)	550	431	468	417	395	320	325	289	281	236	239	214
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Rest of World (ROW) product sales ($M)($M)	164	131	131	124	123	122	106	110	110	106	79	93
EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%)(%)	38.0%	27.0%	39.0%	36.0%	32.0%	29.0%	36.0%	30.0%	39.0%	35.0%	41.0%	53.0%
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide product sales ($M)($M)4	759	727	1,054	1,139	1,122	1,099	1,165	1,045	1,165	999	1,107	986
Prolia (denosumab — Postmenopausal Osteoporosis) — U.S. product sales ($M)($M)	478	461	707	806	745	720	775	683	770	657	746	673
Prolia (denosumab — Postmenopausal Osteoporosis) — Rest of World (ROW) product sales ($M)($M)	281	266	347	333	377	379	390	362	395	342	361	313
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide reported sales growth YoY (%)(%)	-32.0%	-34.0%	-10.0%	9.0%	-4.0%	10.0%	5.0%	6.0%	13.0%	8.0%	12.0%	14.0%
Prolia (denosumab — Postmenopausal Osteoporosis) — Worldwide net selling price change YoY (%)(%)	-12.0%	-10.0%	-8.0%			-5.0%
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide product sales ($M)($M)3											78	94
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — U.S. product sales ($M)($M)	81	68	72	90	64	85	86	77	80	65	73	88
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Rest of World (ROW) product sales ($M)($M)	7	6	7	5	6	5	6	5	5	5	5	6
Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%)											-32.0%	-12.0%

TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide product sales ($M)($M)3	576	490	457	560	505	381	460	488	479	424	448	0
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — U.S. product sales ($M)($M)	520	424	409	518	466	365	456	482	478	419	441	0
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Rest of World (ROW) product sales ($M)($M)	56	66	48	42	39	16	4	6	1	5	7	0
TEPEZZA (teprotumumab-trbw — Thyroid Eye Disease) — Worldwide reported sales growth YoY (%)(%)	14.0%	29.0%	-1.0%	15.0%	5.0%	-10.0%	3.0%
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide product sales ($M)($M)3	400	255	435	320	349	236	346	310	294	235	272	0
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — U.S. product sales ($M)($M)	399	255	435	320	349	236	346	310	294	235	272	0
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Rest of World (ROW) product sales ($M)($M)	1	0	0	0	0	0	0	0	0	0	0	0
KRYSTEXXA (pegloticase — Uncontrolled Chronic Gout) — Worldwide reported sales growth YoY (%)(%)	15.0%	8.0%	26.0%	3.0%	19.0%	0.0%	27.0%
UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — Worldwide product sales ($M)($M)2	335	262	233	155	176	91	101	106	92	80	65
UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — U.S. product sales ($M)($M)	317	246	168	146	132	82	93	74	77	70	60
UPLIZNA (inebilizumab-cdon — NMOSD & IgG4-Related Disease) — Rest of World (ROW) product sales ($M)($M)	18	16	65	9	44	9	8	32	15	10	5
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide product sales ($M)($M)4	150	119	152	107	110	90	81	80	71	51	44	37
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — U.S. product sales ($M)($M)	143	114	142	101	103	77	76	74	61	45	42	32
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Rest of World (ROW) product sales ($M)($M)	7	5	10	6	7	13	5	6	10	6	2	5
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide reported sales growth YoY (%)(%)	36.0%	32.0%	88.0%	34.0%	55.0%	76.0%	84.0%
TAVNEOS (avacopan — ANCA-Associated Vasculitis) — Worldwide volume growth YoY (%)(%)		55.0%	69.0%	66.0%
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide product sales ($M)($M)4	149	98	157	200	183	179	214	188	187	169	164
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — U.S. product sales ($M)($M)	144	96	144	195	175	171	205	180	175	166	162
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Rest of World (ROW) product sales ($M)($M)	5	2	13	5	8	8	9	8	12	3	2
Ultra-Rare Products (RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL & QUINSAIR) — Worldwide reported sales growth YoY (%)(%)	-19.0%	-45.0%	-27.0%	6.0%	-2.0%	6.0%	30.0%
PROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M)($M)1	71	47	59	62	55	57	61	57	54	49
PROCYSBI — Rest of World (ROW) sales ($M)($M)	3	1	2	1	2	2	2	1	4	1

TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide product sales ($M)($M)4	486	343	474	377	342	285	296	269	234	173	177	161
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — U.S. product sales ($M)($M)	486	343	474	377	342	285	296	269	234	173	177	161
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Rest of World (ROW) product sales ($M)($M)	0	0	0	0	0	0	0	0	0	0	0	0
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide reported sales growth YoY (%)(%)	42.0%	20.0%	60.0%	40.0%	46.0%	65.0%	67.0%	67.0%	76.0%	80.0%
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide volume growth YoY (%)(%)		32.0%	51.0%	48.0%
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide product sales ($M)($M)4	491	431	625	585	618	437	624	564	544	394	629	567
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — U.S. product sales ($M)($M)	431	352	511	473	512	343	514	460	432	293	526	462
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Rest of World (ROW) product sales ($M)($M)	60	79	114	112	106	94	110	104	112	101	103	105
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide reported sales growth YoY (%)(%)	-21.0%	-1.0%	0.0%	4.0%	14.0%	11.0%	-1.0%	-1.0%	-9.0%	1.0%	2.0%	-10.0%
Otezla (apremilast — Plaque Psoriasis & Psoriatic Arthritis) — Worldwide volume growth YoY (%)(%)	-6.0%	-2.0%		6.0%	4.0%	4.0%	5.0%	5.0%	2.0%		3.0%	1.0%
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide product sales ($M)($M)4	580	320	532	580	604	510	1,015	825	909	567	1,015	1,035
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — U.S. product sales ($M)($M)	574	314	524	574	597	504	1,008	817	902	561	1,005	1,026
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Rest of World (ROW) product sales ($M)($M)	6	6	8	6	7	6	7	8	7	6	10	9
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide reported sales growth YoY (%)(%)	-4.0%	-37.0%	-48.0%	-30.0%	-34.0%	-10.0%		-20.0%	-15.0%	-2.0%	-8.0%	-6.0%
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide net selling price change YoY (%)(%)	-22.0%	-15.0%	-35.0%	-38.0%	-19.0%	-47.0%		-12.0%
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Worldwide product sales ($M)($M)2	287	280	258	213	130	99	31
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — U.S. product sales ($M)($M)	280	276	254	212	126	99
PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Rest of World (ROW) product sales ($M)($M)	7	4	4	1	4
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide product sales ($M)($M)3	155	173	174	154	133	136	294	166	133	168	160	152
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — U.S. product sales ($M)($M)	26	41	28	16		4	153	28	-9	30	33	23
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Rest of World (ROW) product sales ($M)($M)	129	132	146	138	133	132	141	138	142	138	127	129
AMJEVITA / AMGEVITA (adalimumab-atto — Humira Biosimilar) — Worldwide reported sales growth YoY (%)(%)	17.0%	27.0%	-41.0%	-7.0%		-19.0%	84.0%	9.0%	-11.0%	2.0%	34.0%	30.0%
WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Worldwide product sales ($M)($M)1	61	47	44	44	35	150	21	5		1
WEZLANA / WEZENLA (ustekinumab-auub — Stelara Biosimilar) — Rest of World (ROW) product sales ($M)($M)	61	43	44	44	35	27	21	5		1

BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide product sales ($M)($M)3	472	415	413	392	384	370	381	327	264	244	241	220
BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — U.S. product sales ($M)($M)	285	221	270	236	270	273	245	237	165	153	148	147
BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Rest of World (ROW) product sales ($M)($M)	187	194	143	156	114	97	136	90	99	91	93	73
BLINCYTO (blinatumomab — CD19 BiTE Immuno-Oncology, ALL) — Worldwide reported sales growth YoY (%)(%)	23.0%	12.0%	8.0%	20.0%	45.0%	52.0%	58.0%	49.0%	28.0%	26.0%	47.0%	55.0%
IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — Worldwide product sales ($M)($M)2	288	258	234	178	134	81	67	36	12
IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — U.S. product sales ($M)($M)	233	188	183	144	107	79	67	36	12
IMDELLTRA / IMDYLLTRA (tarlatamab-dlle — DLL3 BiTE, Small Cell Lung Cancer) — Rest of World (ROW) product sales ($M)($M)	55	70	51	34	27	2
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide product sales ($M)($M)4	338	287	319	284	305	267	246	282	270	247	251	252
Vectibix (panitumumab — Metastatic Colorectal Cancer) — U.S. product sales ($M)($M)	167	136	163	162	144	135	134	132	133	120	116	116
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Rest of World (ROW) product sales ($M)($M)	171	151	156	122	161	132	112	150	137	127	135	136
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide reported sales growth YoY (%)(%)	11.0%	7.0%	30.0%	1.0%	13.0%	8.0%	-2.0%	12.0%	9.0%	6.0%	5.0%	2.0%
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%)(%)		11.0%	23.0%				-4.0%					4.0%
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide product sales ($M)($M)4	314	330	351	359	378	324	372	378	377	376	350	349
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — U.S. product sales ($M)($M)	201	218	240	225	232	216	236	238	240	234	222	231
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Rest of World (ROW) product sales ($M)($M)	113	112	111	134	146	108	136	140	137	142	128	118
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide reported sales growth YoY (%)(%)	-17.0%	2.0%	-6.0%	-5.0%	0.0%	-14.0%	6.0%	8.0%	9.0%	5.0%	8.0%	10.0%
KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%)(%)												8.0%
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide product sales ($M)($M)4	430	412	385	457	369	313	337	456	346	317	386	419
Nplate (romiplostim — Immune Thrombocytopenia) — U.S. product sales ($M)($M)	275	283	265	333	228	201	221	345	214	190	252	322
Nplate (romiplostim — Immune Thrombocytopenia) — Rest of World (ROW) product sales ($M)($M)	155	129	120	124	141	112	116	111	132	127	134	97
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide reported sales growth YoY (%)(%)	17.0%	32.0%	14.0%	0.0%	7.0%	-1.0%	-13.0%	9.0%	12.0%	-12.0%	-18.0%	45.0%
Nplate (romiplostim — Immune Thrombocytopenia) — Worldwide volume growth YoY (%)(%)	13.0%	8.0%	9.0%					14.0%				43.0%
XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide product sales ($M)($M)3	352	411	447	539	532	566	561	541	562	561	527	519
XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — U.S. product sales ($M)($M)	187	228	291	357	347	360	369	373	399	366	382	374
XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Rest of World (ROW) product sales ($M)($M)	165	183	156	182	185	206	192	168	163	195	145	145
XGEVA (denosumab — Oncology Bone Metastases & Giant Cell Tumor) — Worldwide reported sales growth YoY (%)(%)	-34.0%	-27.0%	-20.0%	0.0%	-5.0%	1.0%	6.0%	4.0%	6.0%	5.0%	9.0%	5.0%
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide product sales ($M)($M)3	111	94	92	96	90	85	85	98	85	82	77	52
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — U.S. product sales ($M)($M)	62	49	47	57	52	55	53	53	55	53	51	48
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Rest of World (ROW) product sales ($M)($M)	49	45	45	39	38	30	32	45	30	29	26	4
LUMAKRAS / LUMYKRAS (sotorasib — KRAS G12C Non-Small Cell Lung Cancer) — Worldwide reported sales growth YoY (%)(%)	23.0%	11.0%	8.0%	-2.0%	6.0%	4.0%	10.0%	88.0%	10.0%	11.0%	8.0%	-31.0%
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide product sales ($M)($M)3	153	150	188	213	191	179	173	195	157	202	188	213
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — U.S. product sales ($M)($M)	106	96	137	156	142	138	108	136	100	105	127	140
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Rest of World (ROW) product sales ($M)($M)	47	54	51	57	49	41	65	59	57	97	61	73
MVASI (bevacizumab-awwb — Avastin Oncology Biosimilar) — Worldwide reported sales growth YoY (%)(%)	-20.0%	-16.0%	9.0%	9.0%	22.0%	-11.0%	-8.0%	-8.0%	-20.0%		-8.0%	2.0%
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide product sales ($M)($M)3											42	20
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — U.S. product sales ($M)($M)											31	7
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Rest of World (ROW) product sales ($M)($M)											11	13
KANJINTI (trastuzumab-anns — Herceptin Biosimilar, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%)											-33.0%	-72.0%
Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide product sales ($M)($M)3	352	311	333	357	359	340	308	337	348	349	319	323
Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — U.S. product sales ($M)($M)	94	77	115	103	107	91	90	105	91	100	107	107
Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Rest of World (ROW) product sales ($M)($M)	258	234	218	254	252	249	218	232	257	249	212	216
Aranesp (darbepoetin alfa — Nephrology & Oncology Anemia) — Worldwide reported sales growth YoY (%)(%)	-2.0%	-9.0%	8.0%	6.0%	3.0%	-3.0%	-3.0%	4.0%	-5.0%	-2.0%	-8.0%	-10.0%
Neulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide product sales ($M)($M)2	179	165	132	92	82	129	98	110	105	118	239	124
Neulasta (pegfilgrastim — Febrile Neutropenia) — U.S. product sales ($M)($M)	164	149	115	72	63	109	72	84	75	87	208	92
Neulasta (pegfilgrastim — Febrile Neutropenia) — Rest of World (ROW) product sales ($M)($M)	15	16	17	20	19	20	26	26	30	31	31	32
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide product sales ($M)($M)3	101	87	89	84	92	88	75	70	106	105	89	95
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — U.S. product sales ($M)($M)	54	43	49	42	51	50	39	32	67	65	57	59
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Rest of World (ROW) product sales ($M)($M)	47	44	40	42	41	38	36	38	39	40	32	36
Parsabiv (etelcalcetide — Secondary Hyperparathyroidism) — Worldwide reported sales growth YoY (%)(%)	10.0%	-1.0%	19.0%	20.0%	-13.0%	-16.0%	-16.0%	-26.0%	22.0%	15.0%	-4.0%	-5.0%
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide product sales ($M)($M)2							19	33	32	41	55	50
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — U.S. product sales ($M)($M)							19	33	32	41	55	50
EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — Worldwide reported sales growth YoY (%)(%)							-65.0%	-34.0%	-48.0%	-32.0%	-52.0%	-63.0%
Other Products (Segment Note 2 Aggregate) — Worldwide product sales ($M)($M)4	1,697	1,528	2,073	1,853	1,380	1,475	1,568	1,363	1,326	1,373	1,376	1,004
Other Products (Segment Note 2 Aggregate) — U.S. product sales ($M)($M)	1,283	1,131	1,530	1,408	990	1,109	1,179	958	937	963	1,036	675
Other Products (Segment Note 2 Aggregate) — Rest of World (ROW) product sales ($M)($M)	414	397	543	445	390	366	389	405	389	410	340	329
Biosimilars Included in Other Product Sales — Worldwide ($M)($M)	199	185	189	151	172	171	218	148	183	176	93	104
Other Residual Products (8-K Schedule) — Worldwide ($M)($M)3	351	315	320	317	334	340	361	281	346	357	175	167
Other Residual Products (8-K Schedule) — U.S. ($M)($M)	304	263	263	267	278	283	294	228	292	301	137	136
Other Residual Products (8-K Schedule) — Rest of World (ROW) ($M)($M)	47	52	57	50	56	57	67	53	54	56	38	31
Other Residual Products (8-K Schedule) — Worldwide growth YoY (%)(%)	5.0%	-7.0%	-2.0%	3.0%	-12.0%	-14.0%	22.0%		13.0%	16.0%	9.0%	1.0%

Accrued Sales Deductions Liability — Balance Sheet Ending Reserve ($M)1
Operating Cash Flow — Change in Accrued Sales Incentives & Allowance ($M)($M)	1,117	-839	-232	1,184	627	486	658	929	-77	-316	520	242
Collaborations — AstraZeneca (TEZSPIRE) Profit Share Recorded in Cost of Sales ($M)1
BeiGene / BeOne Oncology Collaboration — R&D Cost Recovery ($M)1
BeiGene / BeOne Medicines — Amgen Equity Ownership Stake (%)(%)	17.0%	17.0%	17.0%				17.8%	18.0%	18.0%		18.0%

R&D Expense by Stage (10-K MD&A) — Total R&D Expense ($M)($M)1	1,868	1,719	2,142	1,900	1,744	1,486	1,724	1,450	1,447	1,343	1,534	1,079
R&D Expense Excluding Software (Segment Disaggregation Note 2) ($M)($M)	1,868	1,719	2,142	1,900	1,744	1,486	1,724	1,450	1,447	1,343
Non-GAAP Operating Income ($M)($M)2	4,612	3,721	4,006	4,305	4,293	3,599	4,033	4,044	3,873	3,078	3,660	3,403
GAAP Operating Income ($M)($M)	3,514	2,666	2,720	2,526	2,656	1,178	2,311	2,047	1,909	991	1,271	2,021
Non-GAAP Operating Margin as % of Product Sales (%)(%)1	48.4%	45.3%	42.8%	47.1%	48.9%	45.7%	46.3%	49.6%	48.2%	43.2%	46.7%	52.0%
GAAP Operating Margin as % of Product Sales (%)(%)	36.8%	32.4%	29.0%	27.6%	30.3%	15.0%	26.5%	25.1%	23.7%	13.9%	16.2%	30.9%
Non-GAAP Cost of Sales ($M)($M)2	1,874	1,603	1,790	1,662	1,551	1,420	1,536	1,454	1,406	1,340	1,278	1,137
GAAP Cost of Sales ($M)($M)	2,811	2,744	2,976	3,082	3,011	2,968	3,112	3,310	3,236	3,200	3,112	1,806
Non-GAAP Cost of Sales as % of Product Sales (%)(%)1	19.6%	19.5%	19.1%	18.2%	17.7%	18.0%	17.6%	17.8%	17.5%	18.8%	16.3%	17.4%
GAAP Cost of Sales as % of Product Sales (%)(%)	29.5%	33.4%	31.8%	33.7%	34.3%	37.7%	35.7%	40.6%	40.2%	45.0%	39.7%	27.6%
Non-GAAP Research & Development Expense ($M)($M)2	1,851	1,711	2,133	1,890	1,685	1,475	1,698	1,440	1,423	1,317	1,494	1,070
GAAP Research & Development Expense ($M)($M)	1,868	1,719	2,142	1,900	1,744	1,486	1,724	1,450	1,447	1,343	1,534	1,079
Non-GAAP R&D Expense as % of Product Sales (%)(%)1	19.4%	20.8%	22.8%	20.7%	19.2%	18.7%	19.5%	17.7%	17.7%	18.5%	19.1%	16.3%
GAAP R&D Expense as % of Product Sales (%)(%)	19.6%	20.9%	22.9%	20.8%	19.9%	18.9%	19.8%	17.8%	18.0%	18.9%	19.6%	16.5%
Non-GAAP Selling, General & Administrative Expense ($M)($M)2	1,717	1,583	1,937	1,700	1,650	1,655	1,819	1,565	1,686	1,712	1,764	1,293
GAAP Selling, General & Administrative Expense ($M)($M)	1,745	1,602	1,952	1,720	1,691	1,687	1,878	1,625	1,785	1,808	2,274	1,353
Non-GAAP SG&A Expense as % of Product Sales (%)(%)1	18.0%	19.3%	20.7%	18.6%	18.8%	21.0%	20.9%	19.2%	21.0%	24.1%	22.5%	19.7%
GAAP SG&A Expense as % of Product Sales (%)(%)	18.3%	19.5%	20.8%	18.8%	19.3%	21.4%	21.5%	19.9%	22.2%	25.4%	29.0%	20.7%
Non-GAAP Total Operating Expenses ($M)($M)2	5,442	4,897	5,860	5,252	4,886	4,550	5,053	4,459	4,515	4,369	4,536	3,500
GAAP Total Operating Expenses ($M)($M)	6,540	5,952	7,146	7,031	6,523	6,971	6,775	6,456	6,479	6,456	6,925	4,882
Total Non-GAAP Operating Expense Adjustments ($M)($M)	-1,098	-1,055	-1,286	-1,779	-1,637	-2,421	-1,722	-1,997	-1,964	-2,087	-2,389	-1,382
Non-GAAP Net Income ($M)($M)5	3,423	2,799	2,875	3,055	3,258	2,649	2,879	3,024	2,691	2,140	2,543	2,667
Non-GAAP Income Before Income Taxes ($M)($M)	4,055	3,241	3,440	3,737	3,796	3,103	3,379	3,490	3,163	2,529	3,025	3,178
Non-GAAP Provision for Income Taxes ($M)($M)	632	442	565	682	538	454	500	466	472	389	482	511
Non-GAAP Effective Tax Rate (%)(%)1	15.6%	13.6%	16.4%	18.2%	14.2%	14.6%	14.8%	13.4%	14.9%	15.4%	15.9%	16.1%
GAAP Effective Tax Rate (%)(%)	14.2%	12.7%	12.0%	18.0%	8.7%	12.3%	19.8%	8.7%	6.0%	-66.2%	10.0%	11.1%
Non-GAAP Diluted Earnings Per Share ($/sh)($)1	6.29	5.15	5.29	5.64	6.02	4.90	5.31	5.58	4.97		4.71	4.96
GAAP Diluted Earnings Per Share ($/sh)($)	4.37	3.34	2.45	5.93	2.65	3.20	1.16	5.22	1.38		1.42	3.22
Non-GAAP Free Cash Flow (Operating Cash Flow Less CapEx) ($M)($M)	3,489	1,477	961	4,248	1,911	980	4,400	3,314	2,221	459	289	2,512

Segment Expense Disaggregation (Note 2) — Manufacturing Cost of Sales Excluding Amort & Royalty ($M)($M)5	2,139	2,180	2,325	2,508	2,484	2,528	2,627	2,852	2,825	2,814
Segment Profit Share & Royalty Expense in Cost of Sales ($M)($M)	672	564	651	574	527	440	485	458	411	386
Segment Selling & Marketing Expense ($M)($M)	1,155	1,134	1,290	1,097	1,137	1,066	1,181	1,117	1,211	1,204
Segment General & Administrative Expense ($M)($M)	590	468	662	623	554	621	697	508	574	604
Other Segment Items (Other Operating Expenses & Non-Core Items) ($M)($M)	314	-87	745	-1,642	557	-562	948	-1,661	445	520
Restructuring Charges (legacy standalone disclosure) ($M)($M)											15	31
Inventories — Total Net Carrying Value ($M)($M)3	6,220	6,186	6,225	6,346	6,583	6,729	6,998	7,362	7,995	8,724	9,518	5,026
Inventories — Raw Materials ($M)($M)	1,082	1,048	915	955	885	841	818	788	884	928	993	849
Inventories — Work in Process ($M)($M)	3,470	3,426	3,425	3,555	3,658	3,961	4,120	4,339	4,476	5,270	5,747	2,992
Inventories — Finished Goods ($M)($M)	1,668	1,712	1,885	1,836	2,040	1,927	2,060	2,235	2,635	2,526	2,778	1,185
Property, Plant & Equipment — Total Net Carrying Value ($M)($M)2	8,547	8,216	7,913	7,220	6,855	6,681	6,543	6,156	6,097	6,002	5,941	5,563
Accumulated Depreciation and Amortization of PP&E ($M)($M)	9,400	9,300	11,100	11,000	10,800	10,600	10,388	10,300	10,100	9,900	9,808	9,700
Capital Expenditures Paid ($M)($M)	513	712	642	436	369	411	371	257	238	230	249	248

Goodwill — Carrying Value ($M)($M)1	18,668	18,674	18,680	18,676	18,674	18,645	18,637	18,658	18,616	18,570	18,629	15,509
Goodwill Foreign Currency Translation Adjustment ($M)($M)	-6	-6	4	2	29	8	-21	16	-2	-10	9	-8
Other Intangible Assets — Total Net Carrying Value ($M)($M)7	20,487	21,379	22,276	23,139	24,614	25,724	27,699	28,920	30,172	31,372	32,641	13,150
Other Intangible Assets — Total Gross Carrying Value ($M)($M)	55,016	55,029	55,060	55,011	55,407	55,348	56,122	56,193	56,221	56,230	56,447	35,766
Other Intangible Assets — Total Accumulated Amortization ($M)($M)	34,529	33,650	32,784	31,872	30,793	29,624	28,423	27,273	26,049	24,858	23,806	22,616
Finite-Lived Intangible Assets — Total Net Carrying Value ($M)($M)6	19,777	20,669	21,566	22,429	23,904	24,664	26,639	27,830	29,022	30,222	31,423	12,992
Finite-Lived Intangible Assets — Total Gross Carrying Value ($M)($M)	54,306	54,319	54,350	54,301	54,697	54,288	55,062	55,103	55,071	55,080	55,229	35,608
Finite-Lived Intangible Assets — Total Accumulated Amortization ($M)($M)	34,529	33,650	32,784	31,872	30,793	29,624	28,423	27,273	26,049	24,858	23,806	22,616
Developed Product Technology Rights — Net Carrying Value ($M)($M)2	19,343	20,194	21,051	21,919	23,355	24,081	26,017	27,164	28,301	29,441	30,582	12,097
Developed Product Technology Rights — Gross Carrying Value ($M)($M)	47,793	47,798	47,805	47,803	48,201	47,824	48,611	48,636	48,621	48,625	48,631	29,028
Developed Product Technology Rights — Accumulated Amortization ($M)($M)	28,450	27,604	26,754	25,884	24,846	23,743	22,594	21,472	20,320	19,184	18,049	16,931
Licensing Agreements — Net Carrying Value ($M)($M)2	329	363	395	385	418	450	483	504	535	567	600	631
Licensing Agreements — Gross Carrying Value ($M)($M)	3,902	3,903	3,917	3,875	3,875	3,875	3,875	3,864	3,864	3,864	3,865	3,864
Licensing Agreements — Accumulated Amortization ($M)($M)	3,573	3,540	3,522	3,490	3,457	3,425	3,392	3,360	3,329	3,297	3,265	3,233
Acquired R&D Technology Rights — Net Carrying Value ($M)($M)2	105	112	120	125	131	133	139	147	152	159	166	168
Acquired R&D Technology Rights — Gross Carrying Value ($M)($M)	1,409	1,416	1,425	1,421	1,419	1,387	1,374	1,400	1,383	1,388	1,394	1,377
Acquired R&D Technology Rights — Accumulated Amortization ($M)($M)	1,304	1,304	1,305	1,296	1,288	1,254	1,235	1,253	1,231	1,229	1,228	1,209
Marketing-Related Intangible Assets — Net Carrying Value ($M)($M)2	0	0	0	0	0	0	0	15	34	55	75	96
Marketing-Related Intangible Assets — Gross Carrying Value ($M)($M)	1,202	1,202	1,203	1,202	1,202	1,202	1,202	1,203	1,203	1,203	1,339	1,339
Marketing-Related Intangible Assets — Accumulated Amortization ($M)($M)	1,202	1,202	1,203	1,202	1,202	1,202	1,202	1,188	1,169	1,148	1,264	1,243
Indefinite-Lived In-Process R&D (IPR&D) Intangible Assets ($M)($M)	710	710	710	710	710	1,060	1,060	1,090	1,150	1,150	1,218	158
Intangible Asset Amortization Expense ($M)($M)5	890	896	900	1,100	1,100	1,200	1,200	1,200	1,200	1,200	1,100	693
Estimated Future Intangible Amortization — Year 1 ($M)($M)	3,600	3,600	3,600	3,600	3,700	3,700	4,500	4,500	4,500	4,500	4,800	2,700
Estimated Future Intangible Amortization — Year 2 ($M)($M)	2,800	2,800	3,500	3,500	3,700	3,700	3,900	3,900	3,900	3,900	4,500	2,500
Estimated Future Intangible Amortization — Year 3 ($M)($M)	2,300	2,300	2,800	2,800	2,900	2,800	3,900	3,900	3,900	3,900	3,900	2,100
Estimated Future Intangible Amortization — Year 4 ($M)($M)	2,200	2,200	2,300	2,300	2,300	2,200	2,900	2,900	2,900	2,900	3,900	2,100
Estimated Future Intangible Amortization — Year 5 ($M)($M)	2,100	2,100	2,200	2,200	2,200	2,100	2,200	2,200	2,200	2,200	2,900	1,100
Intangible Asset Impairment Charges ($M)($M)	0	0	0	400	0	800	30	61	0	68
Total Depreciation and Amortization (Cash Flow Statement) ($M)($M)	1,112	1,116	1,132	1,307	1,341	1,387	1,397	1,396	1,400	1,399	1,380	895
Level 3 Contingent Consideration Liabilities — Ending Fair Value ($M)($M)	171	173	161	95	90	104	106	112	107	96	96	98

Total Debt — Carrying Value (Current + Noncurrent) ($M)($M)3	57,304	57,323	54,604	54,587	56,204	57,381	60,099	60,398	62,600	64,000	64,613	60,500
Long-Term Debt — Noncurrent Carrying Value ($M)($M)	51,859	51,886	50,005	52,434	53,760	54,013	56,549	56,854	57,117	60,061	63,170	59,040
Short-Term Debt & Current Portion of Long-Term Debt ($M)($M)	5,445	5,437	4,599	2,153	2,444	3,368	3,550	3,544	5,528	3,959	1,443	1,428
Unamortized Debt Discount and Issuance Costs ($M)($M)	1,317	1,329	1,306	1,317	1,331	1,345	1,360	1,373	1,389	1,404	1,420	1,423
Capital Return — Dividends Declared Per Share ($/sh)4
Dividends Paid Per Share (legacy quarterly disclosure) ($/sh)($)											2.13	2.13
Total Common Stock Dividends Declared ($M)($M)	0	1,362	2,640	1,308	0	1,280	2,487	1,236	0	1,208		1,161
Total Cash Dividends Paid ($M)($M)	1,362	1,358	1,283	1,282	1,280	1,279	1,205	1,210	1,209	1,208	1,140	1,140
Share Repurchases — Cash Paid for Common Stock Repurchased ($M)1
Share Repurchases — Remaining Board Authorization Available ($M)($M)	6,800	6,800	6,800	6,800	6,800	6,800	6,800	7,000	7,000	7,000	7,000	7,000
Stock-Based Compensation (SBC) — Total Pre-Tax Expense ($M)($M)	165	75	125	127	157	85	134	136	157	103	161	104

GAAP Effective Tax Rate (%)(%)	14.2%	12.7%		18.0%	8.7%	12.3%		8.7%	6.0%	-66.2%		11.1%
Deferred Tax Liabilities (DTL) — Total Gross DTL ($M)1
Net Deferred Tax Liabilities Recognized on Balance Sheet ($M)($M)	1,301	1,344	1,366	1,458	1,386	1,510	1,616	1,711	1,780	1,862	2,354
Unrecognized Tax Benefits (UTB Rollforward — IRS Transfer Pricing Dispute) — Ending Gross Balance ($M)2
Unrecognized Tax Benefits Liability Affecting Effective Tax Rate ($M)($M)	2,844	2,764	2,690	2,616	2,511	2,419	2,349	2,280	2,205	3,964	4,680	4,579
UTB Additions Based on Tax Positions Related to Current Year ($M)($M)	45	35	45	45	60	40	68	40	40	40	36	50

U.S. Personal Consumption Expenditures: Health Care Services — SAAR ($B)	3,790.30	3,699.90	3,667.00	3,614.80	3,529.80	3,464.70	3,417.80	3,358.20	3,288.20	3,244.40	3,159.40	3,079.00
Income Statement — Total revenues ($M)($M)17	10,054	8,618	9,866	9,557	9,179	8,149	9,086	8,503	8,388	7,447	8,196	6,903
Cost of sales ($M)($M)	2,811	2,744	2,976	3,082	3,011	2,968	3,112	3,310	3,236	3,200	3,112	1,806
Research and development expense ($M)($M)	1,868	1,719	2,142	1,900	1,744	1,486	1,724	1,450	1,447	1,343	1,534	1,079
Selling, general and administrative expense ($M)($M)	1,745	1,602	1,952	1,720	1,691	1,687	1,878	1,625	1,785	1,808	2,274	1,353
Restructuring charges ($M)($M)											15	31
Total operating expenses ($M)($M)	6,540	5,952	7,146	7,031	6,523	6,971	6,775	6,456	6,479	6,456	6,925	4,882
Operating income ($M)($M)	3,514	2,666	2,720	2,526	2,656	1,178	2,311	2,047	1,909	991	1,271	2,021
Interest expense, net ($M)($M)	673	657	653	685	694	723	747	776	808	824	821	759
Interest and other income, net ($M)($M)	125	101	97	99	86	126	116	126	115	153
Other nonoperating income (expense) ($M)($M)	-73	75	-553	2,080	-394	1,518	-782	1,830	-307	-235	402	685
Income before income taxes ($M)($M)	2,768	2,084	1,514	3,921	1,568	1,973	782	3,101	794	-68	852	1,947
Provision for income taxes ($M)($M)	393	265	181	705	136	243	155	271	48	45	85	217
Net income ($M)($M)	2,375	1,819	1,333	3,216	1,432	1,730	627	2,830	746	-113	767	1,730
Earnings per share — Basic ($/sh)($)	4.40	3.37		5.98	2.66	3.22		5.27	1.39	-0.21		3.23
Earnings per share — Diluted ($/sh)($)	4.37	3.34		5.93	2.65	3.20		5.22	1.38	-0.21		3.22
Weighted-average basic shares (M)(M)	540	540		538	538	538		537	537	536		535
Weighted-average diluted shares (M)(M)	544	544		542	541	541		542	541	536		538
Dividends declared per share ($/sh)($)	0	2.52	2.52	2.38	2.38	2.38	2.25	2.25	2.25	2.25	2.13	2.13
Balance Sheet — Total assets ($M)($M)22	95,639	92,504	90,586	90,141	87,897	89,367	91,839	90,883	90,907	92,980	97,154	90,534
Cash and cash equivalents ($M)($M)	13,989	12,038	9,129	9,445	8,028	8,810	11,973	9,011	9,301	9,708	10,944	34,741
Marketable securities ($M)($M)											0	0
Trade receivables, net ($M)($M)	10,227	9,138	9,570	8,490	8,701	8,132	6,782	7,317	6,934	6,776	7,268	6,145
Inventories ($M)($M)	6,220	6,186	6,225	6,346	6,583	6,729	6,998	7,362	7,995	8,724	9,518	5,026
Other current assets ($M)($M)	4,525	4,113	4,133	3,604	3,422	3,258	3,277	3,076	2,976	2,821	2,602	2,565
Total current assets ($M)($M)	34,961	31,475	29,057	27,885	26,734	26,929	29,030	26,766	27,206	28,029	30,332	48,477
Accumulated depreciation ($M)($M)	-9,400	-9,300	-11,100	-11,000	-10,800	-10,600	-10,388	-10,300	-10,100	-9,900	-9,808	-9,700
Property, plant and equipment, net ($M)($M)	8,547	8,216	7,913	7,220	6,855	6,681	6,543	6,156	6,097	6,002	5,941	5,563
Intangible assets, net ($M)($M)	20,487	21,379	22,276	23,139	24,614	25,724	27,699	28,920	30,172	31,372	32,641	13,150
Goodwill ($M)($M)	18,668	18,674	18,680	18,676	18,674	18,645	18,637	18,658	18,616	18,570	18,629	15,509
Other noncurrent assets ($M)($M)	12,976	12,760	12,660	13,221	11,020	11,388	9,930	10,383	8,816	9,007	9,611	7,835
Accounts payable ($M)($M)	2,865	2,935	2,367	2,838	3,010	2,406	1,908	2,147	2,267	1,628	1,590	1,358
Accrued liabilities ($M)($M)	17,192	16,583	18,523	16,800	15,022	17,234	17,641	14,621	13,722	14,127	15,359	14,168
Total current liabilities ($M)($M)	25,502	24,955	25,489	21,791	20,476	23,008	23,099	20,312	21,517	19,714	18,392	16,954
Long-term debt ($M)($M)	51,859	51,886	50,005	52,434	53,760	54,013	56,549	56,854	57,117	60,061	63,170	59,040
Deferred tax liabilities ($M)($M)	1,301	1,344	1,366	1,458	1,386	1,510	1,616	1,711	1,780	1,862	2,354
Other noncurrent liabilities ($M)($M)	2,445	2,365	2,378	2,223	2,336	2,210	2,349	2,199	2,363	2,357	2,326	2,305
Retained earnings (accumulated deficit) ($M)($M)	-22,275	-24,650	-25,107	-23,800	-25,708	-27,140	-27,590	-25,530	-27,124	-27,870	-26,549	-24,971
Accumulated other comprehensive income (loss) ($M)($M)	-119	-190	-258	-422	-544	-231	-66	-336	-155	-190	-289	-126
Total stockholders' equity ($M)($M)	11,688	9,190	8,658	9,619	7,428	6,207	5,877	7,527	5,925	5,022	6,232	7,656
Total liabilities and stockholders' equity ($M)($M)	95,639	92,504	90,586	90,141	87,897	89,367	91,839	90,883	90,907	92,980	97,154	90,534
Common shares outstanding at period end (M)(M)	541	540	539	539	538	538	537	538	537	536	535	535
Cash Flow Statement — Operating cash flow ($M)($M)12	4,002	2,189	1,603	4,684	2,280	1,391	4,771	3,571	2,459	689	538	2,760
Depreciation and amortization ($M)($M)	222	1,116	1,132	232	220	1,387	1,397	198	202	1,399	1,380	895
Stock-based compensation ($M)($M)	165	75	125	127	157	85	134	136	157	103	161	104
Deferred income taxes ($M)($M)	-291	-176	2	-30	-422	-250	-344	-110	-383	-401	-565	-447
Change in trade receivables ($M)($M)	-1,093	413	-1,075	222	-515	-1,308	473	-342	-176	486	-433	-342
Change in inventories ($M)($M)	-31	18	119	240	239	288	323	681	722	806	573	-54
Change in accounts payable ($M)($M)	-70	571	-484	-174	589	497	-232	-122	643	23	-187	156
Capital expenditures ($M)($M)	513	712	642	436	369	411	371	257	238	230	249	248
Net cash used in investing activities ($M)($M)	-569	-716	-693	-414	-389	-447	-402	-210	-217	-217	-27,089	-262
Proceeds from issuance of long-term debt ($M)($M)	0	3,964			0	0	0	0	0	0	3,996	1
Repayments of long-term debt ($M)($M)	-0	833	-0	1,500	1,000	2,500	-0	2,200	1,400	-0	-0	750
Cash dividends paid ($M)($M)	1,362	1,358	1,283	1,282	1,280	1,279	1,205	1,210	1,209	1,208	1,140	1,140
Net cash used in financing activities ($M)($M)	-1,482	1,436	-1,226	-2,853	-2,673	-4,107	-1,407	-3,651	-2,649	-1,708	2,754	-2,005

19 metrics have no data in the last 12 quarters — .

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics

Fiscal calendar: Amgen Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Amgen operates as a single global human therapeutics operating segment (Note 2), so commercial performance is tracked across 4 Therapeutic Franchises (General Medicine, Rare Disease, Inflammation, Oncology & Established Products) and 35+ commercialized brands disaggregated across United States (U.S.), Rest of World (ROW), and Worldwide (WW) net product sales.
Core commercial & R&D KPIs (Groups 1–6) cover: (1) Consolidated Revenues ($10,054M in Q2 2026 / $36,751M in FY25) and Total Product Sales ($9,567M in Q2 2026 / $35,147M in FY25 across U.S. $6,767M and ROW $2,800M in Q2 2026; U.S. volume +9% and ROW volume +8% YoY in Q2 2026) and General Medicine (Repatha $953M, EVENITY $714M, Prolia $759M in Q2 2026); (2) Rare Disease Franchise acquired via Horizon Therapeutics & ChemoCentryx (TEPEZZA $576M, KRYSTEXXA $400M, UPLIZNA $335M, TAVNEOS $150M, Ultra-Rare Products $168M in Q2 2026 including RAVICTI & PROCYSBI U.S./ROW breakdown); (3) Inflammation & Biosimilars (TEZSPIRE $486M, Otezla $491M, Enbrel $580M, PAVBLU $287M, AMJEVITA $155M, WEZLANA $14M in Q2 2026); (4) Oncology & Established Products (BLINCYTO $472M, IMDELLTRA $288M, Vectibix $338M, KYPROLIS $314M, Nplate $430M, XGEVA $352M, LUMAKRAS $111M, MVASI $153M, Aranesp $352M, Neulasta $92M, Parsabiv $90M in Q2 2026, plus Biosimilars in Other Products $372M in Q2 2026 / $1,422M in FY25); (5) Gross-to-Net (GTN) Sales Deductions Rollforward ($40,664M provisions / 54% of gross product sales and $6,661M ending reserve in FY25 across Rebates $30,275M, Chargebacks $9,081M & Other $1,308M), Top 3 U.S. Wholesalers (McKesson $20,986M / 27%, Cencora $19,708M / 25%, Cardinal Health $13,075M / 17% — combined 69% of worldwide gross revenues and 75% of net trade receivables in FY25), and Collaboration Profit Sharing (AstraZeneca TEZSPIRE, UCB EVENITY, Kyowa Kirin, BeiGene/BeOne); and (6) R&D by Clinical Stage ($7,232M total in FY25: Research & Early Pipeline $2,021M, Later-Stage Clinical Phase 2/3 $3,769M, Marketed Product Support $1,442M) and 8-K GAAP vs. Non-GAAP Reconciliations (48.4% Non-GAAP Operating Margin, $6.29 Non-GAAP Diluted EPS, $3,505M Free Cash Flow in Q2 2026).
Extended operational & ESG KPIs (Groups 7–11) cover: (7) Note 2 Segment Expenses (Manufacturing COGS $1,089M, Profit Share & Royalty COGS $817M, R&D Ex-Software $1,796M, Selling & Marketing $1,226M, G&A $539M in Q2 2026), Inventories by stage ($5,638M net at FY25), and Net PP&E by asset class & geography ($6,568M net at FY25, including $1,334M in Puerto Rico); (8) Goodwill ($18,625M at Q2 2026), Finite-Lived Intangible Assets ($22,256M net at Q2 2026 across Developed Technology, Licensing, Acquired R&D & Marketing-Related), Indefinite-Lived IPR&D ($1,225M), 5-year estimated amortization schedule, and Level 3 Contingent Consideration Rollforward; (9) Debt & 5-year maturity schedule ($53,015M total debt at Q2 2026), Operating Leases ($601M ROU assets / $617M lease liabilities at FY25), Capital Return ($2.52/sh dividend in Q2 2026), and SBC by award type; (10) Income Taxes, DTA/DTL breakdown & Unrecognized Tax Benefits Rollforward ($10,169M gross UTB balance & $5,088M accrued UTB interest/penalties at FY25 related to the IRS Puerto Rico transfer pricing dispute); and (11) Global Workforce (28,200 staff in FY25), CEO Pay Ratio (153:1 / $158,361 median employee in FY25), Form 11-K U.S. Plan ($8,963.48M net assets) & Puerto Rico Plan ($464.56M net assets at FY25), Patient Access ($3.2B U.S. Safety Net Foundation & $232M LMIC donations in FY25), Workplace Safety (0.21 staff TRIR in FY25), and Scope 1, 2 & 3 GHG Emissions, Energy, Water & Waste.
No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Not shown because recent periods are missing (3)

Human Capital, CEO Pay Ratio (DEF 14A), Form 11-K U.S. & Puerto Rico Retirement Plans, Patient Access & Environmental Sustainability › Workplace Safety — Staff Total Recordable Incident Rate (TRIR per 200,000 hours) › Environmental Notices of Violation (NOVs)
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB) › Income Statement — Total revenues ($M) › Gross profit ($M)
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB) › Balance Sheet — Total assets ($M) › Current portion of long-term debt ($M)

Data updated 2026-10-28.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

Amgen Inc (AMGN) operating KPIs

KPIs

Every KPI on its own page

Consolidated Geographic Revenues, Volume/Price Drivers & General Medicine Franchise (Repatha, EVENITY, Prolia)

Rare Disease Franchise (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS & Ultra-Rare Products)

Inflammation & Immunology Biosimilars Franchise (TEZSPIRE, Otezla, Enbrel, PAVBLU, AMJEVITA, WEZLANA)

Oncology & Hematology Franchise (BLINCYTO, IMDELLTRA, Vectibix, KYPROLIS, Nplate, XGEVA, LUMAKRAS) & Established Products

Gross-to-Net (GTN) Deductions Rollforward, Wholesaler Concentration & Strategic Collaborations

R&D Expense by Clinical Stage (10-K MD&A) & GAAP vs. Non-GAAP Operating Reconciliations (8-K)

Segment Expense Disaggregation (Note 2), Inventories by Stage & PP&E by Asset Class & Geography (Puerto Rico Hub)

Goodwill, Intangible Assets by Class, 5-Year Amortization Schedule & Level 3 Contingent Consideration Rollforward

Debt & 5-Year Maturity Schedule, Operating Leases (ASC 842), Capital Return & Stock-Based Compensation

Income Taxes by Jurisdiction, Effective Tax Rate Drivers, DTA/DTL Breakdown & Unrecognized Tax Benefits (UTB) Rollforward

Human Capital, CEO Pay Ratio (DEF 14A), Form 11-K U.S. & Puerto Rico Retirement Plans, Patient Access & Environmental Sustainability

Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements (DB)